Back to Search Start Over

Complex Involvement of Interleukin-26 in Bacterial Lung Infection.

Authors :
Che KF
Paulsson M
Piersiala K
Sax J
Mboob I
Rahman M
Rekha RS
Säfholm J
Adner M
Bergman P
Cardell LO
Riesbeck K
Lindén A
Source :
Frontiers in immunology [Front Immunol] 2021 Oct 28; Vol. 12, pp. 761317. Date of Electronic Publication: 2021 Oct 28 (Print Publication: 2021).
Publication Year :
2021

Abstract

Pneumonia is a global cause of mortality, and this provides a strong incentive to improve the mechanistic understanding of innate immune responses in the lungs. Here, we characterized the involvement of the cytokine interleukin (IL)-26 in bacterial lung infection. We observed markedly increased concentrations of IL-26 in lower airway samples from patients with bacterial pneumonia and these correlated with blood neutrophil concentrations. Moreover, pathogen-associated molecular patterns (PAMPs) from both Gram-negative and -positive bacteria increased extracellular IL-26 concentrations in conditioned media from human models of alveolar epithelial cells, macrophages, and neutrophils in vitro . Stimulation with IL-26 inhibited the inherent release of neutrophil elastase and myeloperoxidase in unexposed neutrophils. This stimulation also inhibited the expression of activity makers in neutrophils exposed to Klebsiella pneumoniae. In addition, priming of human lung tissue ex vivo with exogenous IL-26 potentiated the endotoxin-induced increase in mRNA for other cytokines involved in the innate immune response, including the master Th17-regulator IL-23 and the archetype inhibitory cytokine IL-10. Finally, neutralization of endogenous IL-26 clearly increased the growth of Klebsiella pneumoniae in the macrophage culture. These findings suggest that IL-26 is involved in bacterial lung infection in a complex manner, by modulating critical aspects of innate immune responses locally and systemically in a seemingly purposeful manner and by contributing to the killing of bacteria in a way that resembles an antimicrobial peptide. Thus, IL-26 displays both diagnostic and therapeutic potential in pneumonia and deserves to be further evaluated in these respects.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The editor declared a past collaboration with one of the authors, KC, at the time of review.<br /> (Copyright © 2021 Che, Paulsson, Piersiala, Sax, Mboob, Rahman, Rekha, Säfholm, Adner, Bergman, Cardell, Riesbeck and Lindén.)

Details

Language :
English
ISSN :
1664-3224
Volume :
12
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
34777376
Full Text :
https://doi.org/10.3389/fimmu.2021.761317